Introduction
MHC-encoded class II molecules are heterodimeric cell surface molecules, the function of which is to present peptides to CD4 ϩ thymocytes and peripheral T lymphocytes. They play a critical role in both thymic T cell ontogeny and the activation of peripheral T cell immune responses (1) . Not surprisingly, genetic deficiency of MHC class II results in severe immunodeficiency, which has been called the 'bare lymphocyte syndrome' (2, 3) .
Complementation studies with cells from bare lymphocyte syndrome patients have demonstrated a minimum of four recessive loci, all outside the MHC, and therefore presumably coding for trans-acting regulatory factors (4) . One of these regulatory factors has been identified and designated the class II trans-activator (CIITA) (5) . Since the original identification, the CIITA molecule has been shown to play a critical role in IFN-γ-induced (6) and developmentally regulated (7) class II expression. In many situations, CIITA induction alone is sufficient to induce class II expression (8) . Moreover, CIITA induces the expression of both the invariant chain and HLA-DM locus class II molecules (9) , both of which play crucial roles in the intracellular trafficking, peptide loading and cell surface expression of MHC class II molecules (10) .
The promoter region of class II MHC genes in CIITAdeficient patients is fully occupied by DNA binding proteins (11) . This, together with the fact that CIITA shows no sequence homology to DNA binding proteins, suggests that it might bind to the proteins in the promoter region (5) . The N-terminus has an acidic region, with 30% glutamate or aspartate residues between amino acids 26 and 137. This is followed by three regions rich in proline, serine and threonine (amino acids 163-195, 209-237 and 261-322) (5). Transcriptional activators have been shown to have acidic, proline-rich or glutaminerich regions (for review see 12) , and it was therefore suggested that CIITA might consist of an acidic N-terminal activation domain and a C-terminal domain for binding to MHC class II region promoter proteins (5) . Model studies using fusion proteins of different regions of CIITA with the DNA binding domain of a transcriptional activator have established that the acidic domain is indeed a potent transcriptional activator. All or most transcription activation activity could be ascribed to amino acids 1-125 (13) or 1-114 (14) . The first two proline/serine/threoninerich regions by themselves (amino acids 161-232) had no transcription activation activity (13) . Moreover, the C-terminal 813 amino acids, when fused to a general transcriptional activator, could specifically direct transcription from the DRA promoters, although substantially less potently than the native CIITA molecule (14) .
Distinct functional domains in several transcriptional activators have enabled the construction of dominant negative mutants by deletion of the activation domain, while retaining the DNA binding domain (15) (16) (17) (18) . Whether or not this is possible with CIITA depends on the structural independence of the transcription activation region and the promoter protein binding region. The reduced ability of the 813 amino acid C-terminal region to direct transcription from the DRA promoter suggests that the conformation or other characteristics of this fragment might not be optimal. Indeed, this fragment did not inhibit class II expression in the Raji B lymphoblastoid cell line (14) . As the acidic domain has strong transcription activation activity and the isolated proline-rich domain has none, we have studied mutant molecules lacking the acidic regions only, to leave the longest possible C-terminal fragment.
We report that deleting 151 amino acids from the N-terminal region of human CIITA results in a 979 amino acid molecule which strongly suppresses both constitutive and IFN-γ-induced MHC class II expression. Such a construct has clear potential for regulating MHC class II expression for experimental and clinical purposes.
Methods

Cell culture
The HeLa cell line was maintained in DMEM and the DoHH2 human B lymphoma cell line in RPM1 1640 (both media from Gibco/BRL, Paisley, UK). In each case the medium was supplemented with 10% FCS, 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. For passaging and all other manipulations, the HeLa cells were recovered by scraping. All cultures were at 37°C in 95% air/5% CO 2 .
Induction of MHC class II antigens
Human recombinant IFN-γ (a kind gift of Dr N. Klein, Institute of Child Health, London) was added at 500 units/ ml to HeLa cells at 50% confluence. The cells were harvested 24 and 48 h later. From each cell culture, 5ϫ10 5 cells were used for flow cytometry and 5ϫ10 5 for RT-PCR studies.
mAb
The 16-27-12 (previously called NFKI) mouse IgG1 mAb to HLA-DR was the kind gift of Dr S. Fuggle (Oxford) (19) and the W6/32 mouse IgG1 mAb to human class I MHC antigens was the kind gift of Professor A. F. Williams (Oxford) (20) . The control F16-4-4 mouse IgG1 mAb to rat class I MHC antigens has previously been described in detail (21) .
Flow cytometry
All procedures were at 4°C or on ice, unless otherwise stated. HeLa or DoHH2 cell suspensions were washed twice in 0.5% BSA in PBS and resuspended to 2ϫ10 7 cells/ml in 0.5% BSA/PBS. To 50 µl of the cell suspension (10 6 cells) was added 50 µl of saturating concentrations of mAb diluted in 0.5% BSA/PBS. After 30 min incubation, the cells were washed twice as above and to the pellet of the second wash was added 50 µl of saturating concentrations of fluorescein-labelled rabbit anti-mouse IgG (Dako, High Wycombe, UK) diluted in 0.5% BSA/PBS. The cells were resuspended, incubated for a further 30 min and then washed twice as above. The pellet of the second wash was resuspended in 1 ml of 2% formalin in PBS and 5000 cells were analysed at room temperature in a FACScalibur flow cytometer (Becton Dickinson, NJ).
The data were analysed on CellQuest software (Becton Dickinson). Cells were initially analysed using forward and right angle scatter. With both HeLa and DoHH2 cells, the large majority of cells formed a tight cluster which was gated for the fluorescence studies.
The percentage suppression of MHC class II expression was calculated on the basis of the mean channel of fluorescence for class II of the test cells, standardized to the profile of the test cells with the negative control antibody as the zero point. The mean channel of fluorescence of IFN-γ treated normal cells was taken as 100%. For example, with clone 2 in Fig. 3 , the mean channels of fluorescence with the control antibody and the antibody to HLA-DR were 2.6 and 4.9 respectively. The corresponding figures for the control HeLa clone were 2.7 and 88.1. The percentage suppression was calculated as: 100ϫ[1 -((4.9-2.6)/(88.1-2.7))] ϭ 97.3%.
Construction of CIITA deletion mutants
The full sequence of the CIITA cDNA present in pBlueScript (5) (kindly provided by Dr V. Steimle, Geneva) was moved to the pcDNA3 expression vector using EcoRI and XhoI. pcDNA3mutCIITA2 (Fig. 1A) . This was constructed in two steps. First, the pcDNA3 CIITA construct was cut with NotI and XhoI, and the resulting fragment (representing position 1340 to the 3Ј end of the CIITA) was subcloned into NotI and XhoI sites of pcDNA3. Next, PCR was used to synthesize the fragment from amino acid 152 to the NotI site. The upstream primer, 5Ј-ACTCGATATCATTCCGGCA-GACCTGAAGCAT-3Ј, contained an introduced EcoRV site (under lined) at position 567 of the original sequence, while the downstream primer, 5Ј-GCTCACTGCCCCAGCCCAATA-3Ј, was complementary to the CIITA sequence immediately downstream of the NotI site. The amplified product was cut with EcoRV and NotI, purified on a ChromaspinϩTE-100 column (Clontech, Palo Alto, CA), and inserted at the EcoRV and NotI sites, resulting in pcDNA3mutCIITA2. Following insertion into pcDNA3, the PCR product was sequenced between the EcoRI and NotI sites, and confirmed to correspond exactly to the published sequence (5). This construct was used as a control since it lacked an initiation codon and would not give rise to CIITA protein. Fig. 1B) . In order to support translation of the mutated cDNA, an oligonucleotide containing an initiation codon, followed by five codons corresponding to amino acids 146-150 of native CIITA was incorporated at the 5Ј end of the pcDNA3mutCIITA2 construct. Two complementary oligonucleotides were synthesized containing the ATG initiation codon (underlined) on the sense strand, an EcoRI site at the 5Ј end of the sense strand and a blunt end at the other as follows: 5Ј-AATTCTACACAATGCGTTGCCTGGCTCCA-3Ј and 5Ј-TGGA-GCCAGGCAACGCATTGTGTAG-3Ј. These were annealed to each other by heating at 95°C followed by cooling to room temperature over 3 h. The annealed oligonucleotides were ligated into pcDNA3mutCIITA2 at the EcoRI and EcoRV sites. At the junction of this oligonucleotide with the remainder of the construct, as a consequence of this manipulation, the native codon for a leucine at position 151 was replaced by a codon for isoleucine. This was pcDNA3mutCIITA3.
pcDNA3mutCIITA3 (
pcDNA3mutCIITA4 (Fig. 1B) . In order to ensure transport of the mutated CIITA molecule to the nucleus, another synthetic oligonucleotide construct was made. This was similar to that for pcDNA3mutCIITA3, but contained in addition 21 nucleotides encoding a nuclear localization signal (NLS). The complementary oligonucleotides were: 5Ј-AATTCTACACAATGCGTT-GCCTGGCTCCAAAGAAGAAGCGCAAGGTC-3Ј and 5Ј-GA-CCTTGCGCTTCTTCTTTGGAGCCAGGCAACGCATTGTGTAG-3Ј. This pair of oligonucleotides contained (in addition to the ATG initiation codon, the EcoRI site and the blunt end) the NLS of the SV40 large T antigen (Lys/Lys/Lys/Arg/Arg/Lys/Val) (22, 23) . These were ligated into pcDNA3mutCIITA2 at the EcoRI and EcoRV sites, resulting in pcDNA3mutCIITA4.
pCEP4 vectors (Fig. 1C) . The pcDNA3mutCIITA2, 3 and 4 vectors were cut by EcoRI, treated with Klenow large fragment DNA polymerase to create blunt ends, and subsequently cut with XhoI. These fragments were purified using QiaexII Gel Extraction (Qiagen, Hilden, Germany) and cloned into the expression vector pCEP4 in the PvuII and XhoI sites, to create respectively pCEP4mutCIITA2, 3 and 4.
DNA sequence analysis
The pcDNA3mutCIITA2, 3 and 4 constructs were sequenced between the EcoRI and NotI sites, using four oligonucleotide primers. One primer was complementary to the sequence of the pcDNA3 CMV promoter, 5Ј-ATACGACTCACTATAGG-3Ј. The other three primers were complementary to the original CIITA cDNA sequence (5) at positions 819-838, 1002-1026 and 1180-1208. Then, 10 µl plasmid DNA (1.5 µg/µl) was subjected to sequencing reactions and run on an ALF System (Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer's instructions.
Transfections
HeLa and DoHH2 cells were washed twice in OPTIMEM-1 serum-free medium (Gibco/BRL) and 10 6 cells in 0.8 ml of OPTIMEM-1 were seeded into each well of six-well tissue culture plates (Becton Dickinson). For the transfections, 3 µg of DNA construct and 10 µg of lipofectamine (Gibco/BRL) were mixed in 200 µl of OPTIMEM-1 and incubated for 30 min at room temperature to allow DNA-lipofectamine complexes to form. This was added to the appropriate well on the tissue culture plate, mixed gently to ensure uniform distribution and incubated for 5 h at 37°C in 95% air/5% CO 2 . At the end of this incubation, 4 ml of the appropriate medium with 12.5% FCS was added to each well.
At 48 h after transfection, the HeLa cells were passaged into medium containing 500 µg/ml G418 (Gibco/BRL) The medium was changed every 2 days. Colonies were picked after 2-4 weeks in the selective medium and were maintained in flasks in selective medium.
The DoHH2 cells (which grow as a suspension culture) were taken 48 h after transfection and maintained with 500 µg/ml of G418 in the medium. 
Semi-quantitative RT-PCR analysis
Messenger RNA was prepared from HeLa and DoHH2 cells using an mRNA Purification System (Pharmacia Biotech), and the amount of mRNA recovered was established spectrophotometrically using a GeneQuant (Pharmacia Biotech). Complementary DNA was synthesized using 320 ng mRNA and the First-Strand cDNA Synthesis Kit (Pharmacia Biotech) according to the manufacturer's instructions. The solution was denatured at 95°C for 5 min and different amounts of template (equivalent to 200, 50, 10, 2 and 0.4 ng mRNA) were amplified in the presence of primers specific for actin, endogenous CIITA, HLA-DRA and mutated CIITA as follows:
HLA-DRA chain:
upstream primer: 5Ј-CGAGTTCTCTATCTGAATCCTG-3Ј (from exon 1) downstream primer: 5Ј-GTTCTGCTGCATTGCTTTTGC-3Ј (from exon 2) Endogenous CIITA:
upstream primer: 5Ј-ACTCCGGGAGCTGCTGCCCTGGC-3Ј downstream primer: 5Ј-CCTGGAAGACATACTGGTCC-3Ј Transfected CIITA:
upstream primer: 5Ј-AATTCTACACAATGCGTTGCCTGGCTCCA-3Ј downstream primer: 5Ј-GTTGGGAGGCCGTGGACAGTG-3Ј Actin:
upstream primer: 5Ј-GGGCATGGGTCAGAAGGATT-3Ј (from exon 3) downstream primer: 5Ј-TACATGGCTGGGGTGTTGAA-3Ј (from exon 4)
The upstream primer for the transfected CIITA is from the inserted synthetic oligonucleotide. It therefore cannot recognize endogenous CIITA, but is specific for mutCIITA3 and mutCIITA4.
The upstream primer for endogenous CIITA is from the regions deleted in all mutant constructs. It therefore cannot recognize the mutated CIITAs, but is specific for endogenous CIITA.
Results
Construction of deletion mutants of the human CIITA molecule
Our objective was to remove the smallest portion of the Nterminal region which would completely abolish activation of transcription, in order to give the optimal chance for the remainder of the molecule to retain its native conformation. We chose to remove the first 151 amino acids (bases 1-566) in the first instance All three mutated CIITA constructs were placed in the expression vectors pcDNA3 and pCEP4, in both of which transcription is controlled by the CMV promoter (Fig. 1C) . The pCEP4 vector has the potential to support episomal growth in human cells, via an Epsetin-Barr virus origin of replication.
Base-line studies
RT-PCR experiments demonstrated that neither CIITA nor HLA-DRA mRNA could be detected in HeLa cells prior to stimulation with IFN-γ. However, these were readily detectable within 24 h of stimulation ( Fig. 2A, lanes 1 and 2) . By contrast, the DoHH2 cell line had readily detectable mRNA for both CIITA and HLA-DRA, which was not obviously influenced by exposure to IFN-γ ( Fig. 2A, lanes 3 and 4) .
In agreement with the mRNA data, HLA-DR protein was readily detectable by flow cytometry after, but not before, IFN-γ stimulation of HeLa cells (Fig. 2B, panel 1) . HeLa cells strongly express MHC class I molecules, which are further up-regulated by IFN-γ (Fig. 2B, panel 2) . This provides an excellent control for the class II expression studies. As expected, the DoHH2 cell line strongly and constitutively expressed both HLA-DR and class I molecules (Fig. 2B, panel  3) , and these were not up-regulated by IFN-γ (data not shown). All 28 clones transfected with the empty pcDNA3 vector and all 27 clones transfected with the control CIITA construct without the initiation codon (pcDNA3mutCIITA2) had normal class II MHC induction by flow cytometry. In excess of 10 clones with each construct were also tested by semiquantitative RT-PCR and all gave essentially the same result. A representative clone transfected with pcDNA3mutCIITA2 and analysed by flow cytometry (Fig. 3B, clone 1) and by semi-quantitative RT-PCR (Fig. 3A, clone 1) showed normal class II and class I MHC antigen induction, as well as normal induction of mRNA for CIITA and HLA-DRA.
Suppression of HLA-DR induction in
Thirty-six of 62 HeLa clones transfected with pcDNA3mutCI-ITA3 (with initiation codon) and 54 of 95 HeLa clones transfected with pcDNA3mutCIITA4 (with initiation codon and NLS) showed clear (Ͼ35%) suppression of class II MHC induction. Nineteen of the 36 and 22 of the 54 clones showed very strong suppression of MHC class II induction and were chosen for further study. Flow cytometry profiles for representative clones are shown in Fig. 3(B, clones 2 and 3) , with semi-quantitative RT-PCR analysis on these same cultures in Fig. 3(A, clones 2 and 3) . The flow cytometry demonstrated a down-regulation in mean fluorescence for class II of 97% with pcDNA3mutCIITA3 and 98% with pcDNA3mutCIITA4, without any reduction in class I expression. The RT-PCR studies showed normal induction of endogenous CIITA mRNA in clones 2 and 3 but, in spite of this, a substantial (~20-fold) suppression of HLA-DRA mRNA expression. There was no consistent advantage of pcDNA3mutCIITA4 (with initiation codon and NLS) over pcDNA3mutCIITA3 (with initiation codon only). The variability in effectiveness of the mutated constructs in different clones was presumably a consequence of the fact that the site of integration into the host cell genome can influence the level of gene expression.
None of the HeLa clones expressing the pcDNA3mutCIITA3 or 4 constructs showed any expression of class II antigens prior to IFN-γ stimulation (data not shown). Thus, removal of the N-terminal 151 amino acids abolished transcription activation by CIITA even though the truncated CIITA molecules could presumably bind well to the promoter proteins to compete effectively with native CIITA.
Expression of mutant CIITA mRNA was clearly visible (Fig. 3A, clones 2 and 3, 200 ng gel) . Omission of the RT step resulted, in no PCR products (data not shown), formally demonstrating that the mutated CIITA PCR product was derived from expressed mRNA and not genomic DNA or surviving plasmid DNA.
pCEP4 expression vector. Because of the possibility of higher levels of expression of mutated CIITA from multiple episomal copies, the vector pCEP4 was also used. Transiently transfected HeLa cell cultures were used, but hygromycin selection was applied to remove non-transfected cells.
HeLa cells were transfected with the control mutCIITA2 and the mutCIITA4 constructs in pCEP4. Five to 11 days after selection with hygromycin, the bulk cultures were stimulated with IFN-γ and subjected to flow cytometry and semi-quantitat- ive RT-PCR analysis. The experiment was repeated on 11 occasions. The control cultures transfected with the empty pCEP4 vector (data not shown) or the control pCEP4mutCI-ITA2 construct (Fig. 4A and B, culture 1) showed the expected normal pattern of MHC class I and class II protein expression, and CIITA and HLA-DRA mRNA expression. However, on seven of the 11 occasions, the cultures transfected with pCEP4mutCIITA4 constructs showed Ͼ60% suppression of class II MHC expression, the suppression being Ͼ93% in four of these seven cultures. The results for one of the transfections with the mutCIITA4 construct are given in Fig. 4(A  and B, culture 2) . The down-regulation in mean fluorescence for class II was 99% for this culture and HLA-DRA mRNA was substantially reduced (~20-fold). Expression of the mutant CIITA construct was readily visible in the 200 ng gel.
Suppression of constitutive HLA-DR expression in a B lymphoblastoid cell line by mutated CIITA
The DoHH2 cell line was transiently transfected with each of the pcDNA3mutCIITA constructs, but G418 selection was applied to remove non-transfected cells. At days 5 and 8 following selection with G418, the cultures were examined by flow cytometry and semi-quantitative RT-PCR. The experiment was repeated on 20 occasions. For any particular experiment, the results at days 5 and 8 were very similar.
The flow cytometry studies showed no suppression of class I MHC expression at any stage in any of the cultures (data not shown). Flow cytometry studies for MHC class II expression are given in Fig. 5(B) . Cultures transfected with pcDNA3 alone (culture 1) or pcDNA3mutCIITA2 (culture 2) (data not shown) showed no reduction in class II expression. However, 11 of 20 cultures transfected with pcDNA3mutCIITA3 showed Ͼ35% suppression of MHC class II expression, with four of these showing Ͼ75% suppression. One of these latter cultures, showing 87% suppression, is illustrated in Fig. 5(B,  panel 1, culture 3) . Eight of the 20 cultures transfected with pcDNA3mutCIITA4 showed Ͼ35% suppression of MHC class II suppression, with four of these showing Ͼ80% suppression. One of these latter cultures, showing 89% suppression, is illustrated in Fig. 5(B, panel 2, culture 4) . There was no suppression of endogenous CIITA mRNA expression in any of the cultures (Fig. 5A) . However, in the pcDNA3mutCIITA3 (Fig. 5A, culture 3 ) and pcDNA3mutCIITA4 (Fig. 5A, culture  4) (14) . It would therefore seem likely that this region of CIITA either plays a critical role in the conformation of the remainder of the protein or is itself directly involved in critical protein-protein interactions. Our mutated CIITA proteins might function as dominant negative suppressors by competing effectively with endogenously produced CIITA for binding to proteins in the promoter region of MHC class II genes. However, the relative expression of endogenous CIITA mRNA and mutant CIITA mRNA in the transfected cell lines cannot be assessed from our RT-PCR studies, as the efficiency of the primers for PCR is likely to vary for the two molecules. Whereas a long strand of sequence was available to select the optimal upstream primer specific for endogenous CIITA, that for mutant CIITA was restricted to the inserted oligonucleotide containing the initiation codon. Nevertheless, it is worth noting that transcription activators frequently are active as dimers or higher multimers (e.g. 16, 24, 25) . If this is the case for CIITA, it is possible that in addition to competing for binding to proteins in the promoter region, the mutated proteins either are unable to form multimers, or that dimers or multimers incorporating a mutant CIITA molecule are functionally compromised. In these circumstances the suppressive effect of mutated CIITA molecules would be greater than would be expected from the relative concentrations of endogenous and mutated forms.
Although the region of the CIITA protein important for nuclear localization is not known, our studies suggest that it is not present in the N-terminal 151 amino acids. This can be inferred from the equal effectiveness of mutant constructs, irrespective of whether or not a known NLS is added As NLS tend to be basic (26) , one would in fact not expect this signal to be in the acidic region of the molecule.
The suppression of MHC class II expression by these mutant CIITA proteins has potentially important applications for regulating clinically relevant immune responses, especially in autoimmunity and transplantation. For example, it has been suggested that class II MHC expression on vascular endothelial cells plays a critical role in the long-term immunogenicity of transplanted human organs (27) . The suppression of this expression might substantially reduce the incidence of chronic rejection and the requirement for long-term immunosuppression. In the pig-to-human xenograft system, it is now well established that human T cells can respond directly to porcine MHC class II molecules (28) and these molecules therefore present potentially important targets for immune regulation. It is important to note, from studies down-regulating MHC expression in B cells by antisense oligonucleotides, that partial suppression of MHC expression on antigen-presenting cells can have major effects on the efficacy of antigen presentation (29) . For experimental studies, the in vivo down-regulation of class II expression has been possible by the use of the gene knock-out approach, in particular for CIITA (30) . These approaches give rise to global suppression of class II MHC genes. Our construct would allow tissue-specific down-regulation, by the generation of transgenic mice carrying the mutant CIITA genes under tissue specific promoters.
